Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene

A technology of tumor dissolution and immune induction, applied in the direction of non-active ingredient medical preparations, medical preparations containing active ingredients, viruses, etc., can solve difficult, difficult gene recombination, efficient and standardized production of conditional replication adenovirus Technology does not exist and other issues
CN111542601APending Publication Date: 2020-08-14KAGOSHIMA UNIV
25 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
KAGOSHIMA UNIV
Publication Date
2020-08-14

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A purpose of the present invention is to develop an immuno-viral therapy vector that has an optimal therapeutic effect while ensuring a high degree of safety, on the basis of the novel concept of finding the optimal expression level of a therapeutic gene to bring about the maximum therapeutic effect with no side effects. The present invention provides an oncolytic virus or similar that is characterized by having an immunogenic gene that is functionally linked downstream of an E2F promoter or a promoter demonstrating the same activity as an E2F promoter, wherein a promoter of nucleic acids coding for at least one factor that is essential for virus replication or assembly is substituted with a promoter of a factor for which expression is organ-specifically enhanced, or a promoter of a factorfor which expression is cancer cell-specifically enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of cancer therapy, so-called oncolytic immunotherapy, using oncolytic viruses loaded with immune-inducing genes. Background technique

[0002] Oncolytic immunotherapy is an immunotherapy that loads an immune-inducing gene into an oncolytic virus, which is a genetically recombinant virus that specifically proliferates in cancer cells and exhibits a killing effect. , which is expected to be the most powerful candidate for innovative cancer treatment drugs in the world (Non-Patent Document 1-Non-Patent Document 3), at the end of 2015, Europe and the United States approved the T-Vec gene loaded with cytokine genes (Amgen's T-Vec ) medicines as First-in-class (epoch-making medicines).

[0003] In the early 1990s of gene therapy, the inventors of the present invention were the first in the world to develop immune gene therapy by introducing immune genes using non-proliferative viral vectors (Non-Patent Documents 4 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More